Pharmafile Logo

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.

CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs).

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin’s Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal Cell Carcinoma (RCC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN). 

Find out more https://www.researchpartnership.com/news/2017/06/therapy-watch-expands-oncology-and-ibd-portfolios/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

First, we need to talk: mental healthcare in the MENA region

In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...

Sabera Hyderally appointed Head of MedTech North America

Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.